News
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
Scripps News on MSN3d
FDA Approves Merck’s Enflonsia to prevent RSV in infantsThe Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results